Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 7/20 | 0.56 |
| ▸ | NPC1 | O15118 | 7/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.55 |
| ▸ | HTT | P42858 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5370226 | 0.87 | EGFR (0.57) | EGFRRAB9ANPC1KMT2AMEN1 | |
| SCHEMBL8314670 | 0.87 | EGFR (0.57) | EGFRRAB9ANPC1KMT2AMEN1 | |
| SCHEMBL9891820 | 0.86 | EGFR (0.49) | EGFRRAB9ANPC1KMT2AMEN1 | |
| SCHEMBL13413838 | 0.86 | EGFR (0.46) | EGFRRAB9ANPC1KMT2AMEN1 | |
| SCHEMBL21479384 | 0.84 | EGFR (0.44) | EGFRRAB9ANPC1KMT2AMEN1 | |
| SCHEMBL1619382 | 0.83 | EGFR (0.54) | EGFRRAB9ANPC1KMT2AMEN1 | |
| SCHEMBL2951112 | 0.82 | RAB9A (0.77) | EGFRRAB9ANPC1KMT2AMEN1 | |
| SCHEMBL9891816 | 0.82 | EGFR (0.46) | EGFRRAB9ANPC1KMT2AMEN1 | |
| SCHEMBL11394254 | 0.82 | EGFR (0.56) | EGFRRAB9ANPC1KMT2AMEN1 | |
| SCHEMBL1621838 | 0.81 | EGFR (0.51) | EGFRRAB9ANPC1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4293328-A | N-(5-t-Butyl-3-isoxazolyl)alkanamide derivatives and herbicidal compositions containing them | SHIONOGI & CO., LTD. (JP) | 1981-10-06 | — | — | US | claimed |
| US-11384076-B2 | Synthesis, pharmacology and use of new and selective FMS-like tyrosine kinase 3 (FLT3) FLT3 inhibitors | UNIVERSITÄT REGENSBURG (DE) | 2022-07-12 | — | — | US | disclosed |
| US-10870647-B2 | Imidazopyridine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for preventing or treating cancer | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2020-12-22 | — | — | US | disclosed |
| US-20200190075-A1 | SYNTHESIS, PHARMACOLOGY AND USE OF NEW AND SELECTIVE FMS-LIKE TYROSINE KINASE 3 (FLT3) FLT3 INHIBITORS | UNIVERSITÄT REGENSBURG (DE) | 2020-06-18 | — | — | US | disclosed |
| US-20190315738-A1 | NOVEL IMIDAZOPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING CANCER | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2019-10-17 | — | — | US | disclosed |
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| US-4293328-A | N-(5-t-Butyl-3-isoxazolyl)alkanamide derivatives and herbicidal compositions containing them | SHIONOGI & CO., LTD. (JP) | 1981-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11384076-B2 | Synthesis, pharmacology and use of new and selective FMS-like tyrosine kinase 3 (FLT3) FLT3 inhibitors | FLT3, CSF3R, ABL1 | EGFR 51/4885RAB9A 4286/4885NPC1 3493/4885 |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | EGFR 970/4885RAB9A 2299/4885NPC1 1904/4885 |
| US-20190315738-A1 | NOVEL IMIDAZOPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING CANCER | FYN, SRC, LCK | EGFR 125/4885RAB9A 3379/4885NPC1 4146/4885 |
| US-20200190075-A1 | SYNTHESIS, PHARMACOLOGY AND USE OF NEW AND SELECTIVE FMS-LIKE TYROSINE KINASE 3 (FLT3) FLT3 INHIBITORS | FLT3, CSF3R, ABL1 | EGFR 51/4885RAB9A 4286/4885NPC1 3493/4885 |
| US-10870647-B2 | Imidazopyridine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for preventing or treating cancer | FYN, SRC, LCK | EGFR 132/4885RAB9A 3553/4885NPC1 4250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.